You are here: Industry Insights > Paxlovid

News List

Health Canada grants authorisation to Pfizer’s Paxlovid for Covid-19 Pharmaceutical-Technology
January 19, 2022
The authorised dosage is two tablets of nirmatrelvir and one tablet of ritonavir given orally twice daily for five days.
Pfizer to boost COVID-19 pill production with French deal ExpressPharma
January 18, 2022
The decision is part of Pfizer's strategy to boost global production of the pill, Paxlovid, which was found to be nearly 90 per cent effective in preventing hospitalisations and deaths in patients at high risk of severe illness...
Oral COVID-19 antivirals market set for growth CPhIonline
January 13, 2022
Lagevrio and Paxlovid are the only COVID-19 pills cleared for emergency use at present, but others are coming with developers racing to bring oral antivirals to this potentially lucrative market.
Pentarlandir Proves Effective Against COVID-19 Variants in Preclinical Studies contractpharma
January 06, 2022
Costs for the drug are expected to be significantly lower than for Pfizer’s Paxlovid.
Britain approves Pfizer’s anti-viral COVID-19 pill Paxlovid ExpressPharma
January 04, 2022
Britain has approved Pfizer’s COVID-19 pill for adults who have mild-to-moderate infection and are at high risk of their illness worsening, its second easily administered antiviral against the coronavirus.
UK MHRA grants approval to Pfizer’s oral antiviral for Covid-19 Pharmaceutical-Technology
January 04, 2022
In a trial, Paxlovid, given within three days of symptom onset, lowered hospitalisation and death risk within 28 days by 89%.
MHRA grants approval for Pfizer’s oral COVID-19 antiviral pill pharmatimes
January 04, 2022
Pfizer’s Paxlovid has a success rate of nearly 90% as a prophylaxis treatment against severe COVID-19 when administered shortly after the patient has been infected with the virus.
Pfizer to deliver 2.5 million additional doses of Covid-19 pill to UK Pharmaceutical-Business-Review
December 24, 2021
The agreement with the Government of the UK is subject to the local authorisation of the Covid-19 pill.
FDA grants EUA for Pfizer’s Covid-19 oral antiviral Paxlovid Pharmaceutical-Technology
December 24, 2021
The US Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for Pfizer’s oral antiviral Paxlovid to treat mild-to-moderate Covid-19 in adults and paediatric individuals aged 12 years and above.
Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 prnewswire
December 23, 2021
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer's Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease...

Previous page 1 2 3 4 Next page